Assessment of exposure to drug use and psychosocial stress is complicated by the fact that each is often transient and difficult to recall accurately. Assessment of their causal connections with one another, and of their genetic and environmental determinants, is complicated by the complexity of the causal connections and by the elusive nature of what constitutes the """"""""environment."""""""" In the proposed study, we will assess drug use and psychosocial stress in near-real time through Ecological Momentary Assessment (EMA), in which participants use handheld electronic diaries to record events as they occur and to report recent or ongoing events in response to randomly timed prompts throughout the day. We will also maintain real-time records of where the reported events occurred by having participants carry Global Positioning System (GPS) devices to track their whereabouts with a likely spatial resolution of several meters. Broadening the definition of environmental factors, we will evaluate 'neighborhood-level'exposures to drugs and stress measured in terms of specially developed indices, the Drug Environment Index (DEI) and the Neighborhood Psychosocial Hazards index (NPH), each based on objective statistical data available from public sources and independent of self-report. For comparison, drug use exposure will also be assessed through retrospective audio-computer assisted structure interview (ACASI) and from biological specimens (hair and sweat), and stress will be assessed through ACASI and physiological measures (heart rate and allostatic load). The project represents a collaboration between the NIDA Intramural Research Program (where EMA is already in use with polydrug-dependent outpatients) and Johns Hopkins ALIVE Study investigators (following a well- characterized community cohort of drug abusers, most of who are not in treatment). Following developmental work at NIDA linked to field trials in ALIVE, the result is expected to be a set of field- deployable, state-of-the-art tools indispensable to future studies of gene-environment interactions affecting drug use and stress.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DA023832-04
Application #
7825378
Study Section
Special Emphasis Panel (ZDA1-MXS-M (10))
Program Officer
Lambert, Elizabeth
Project Start
2007-08-14
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
4
Fiscal Year
2010
Total Cost
$452,188
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kandathil, Abraham J; Breitwieser, Florian P; Sachithanandham, Jaiprasath et al. (2017) Presence of Human Hepegivirus-1 in a Cohort of People Who Inject Drugs. Ann Intern Med 167:1-7
Cassol, Edana; Misra, Vikas; Morgello, Susan et al. (2015) Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression. J Acquir Immune Defic Syndr 69:18-28
Piggott, Damani A; Varadhan, Ravi; Mehta, Shruti H et al. (2015) Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use. J Gerontol A Biol Sci Med Sci 70:1542-7
Dudley, Dawn M; Bailey, Adam L; Mehta, Shruti H et al. (2014) Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq. Retrovirology 11:122
Labrique, Alain B; Kirk, Gregory D; Westergaard, Ryan P et al. (2013) Ethical issues in mHealth research involving persons living with HIV/AIDS and substance abuse. AIDS Res Treat 2013:189645
Kirk, Gregory D; Linas, Beth S; Westergaard, Ryan P et al. (2013) The exposure assessment in current time study: implementation, feasibility, and acceptability of real-time data collection in a community cohort of illicit drug users. AIDS Res Treat 2013:594671
Gravitt, Patti E; Kirk, Gregory D (2010) Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease. J Infect Dis 201:650-2